Matthew Angel

Sumitomo Pharma America, Inc. operates as a biopharmaceutical company that develops pharmaceutical products. Its products include Aptiom (eslicarbazepine acetate) tablets, Latuda (lurasidone HCl) tablets, Lunesta (eszopiclone) tablets, Xopenex (levalbuterol HCl) Inhalation Solution, Xopenex HFA (levalbuterol tartrate) Inhalation Aerosol, Brovana (arformoterol tartrate) Inhalation Solution, Omnaris (ciclesonide) Nasal Spray, Alvesco (ciclesonide) Inhalation Aerosol, and Zetonna (ciclesonide) Nasal Aerosol. The company was founded in 2010 and is headquartered in Marlborough, MA.

Frazier Management LLC (Frazier Healthcare Partners) is a venture capital subsidiary of Frazier & Co Inc. founded in 1991. The firm is headquartered in Seattle, Washington.

Oxford Bioscience Partners is an Independent Venture Capital firm founded in 1992 by Edmund Martin Olivier, Alan G. Walton and Cornelius T. Ryan. The firm is headquartered in Boston.

Brighton Biotech, Inc. provides medical research services. It specializes in acquiring and developing pharmaceutical and biotechnology products intended for the treatment and prevention of serious unmet medical needs. The company was founded in 2010 and is headquartered in New York, NY.

Nabriva Therapeutics GmbH is a clinical-stage biopharmaceutical company, which engages in the research and development of novel anti-infective agents to treat serious infections. It focuses on the pleuromutilin class of antibiotics. The company was founded by Rodger Novak in October 2005 and is headquartered in Vienna, Austria.

Part of Pfizer Inc., Pfizer (St. Louis) is a private company that provides research services in prescription medicines for humans and animals. The company is based in Chesterfield, MO.

Deciphera Pharmaceuticals LLC discovers and develops pharmaceutical preparations. It designs kinase inhibitor therapies that target the hallmarks of cancer biology. The firm’s clinical pipeline of kinase inhibitors includes tumor-targeted therapies and immuno-targeted therapies. It offers DCC-2618, Rebastinib, and DCC-3014. The company was founded by Daniel L. Flynn in 2003 and is headquartered in Waltham, MA.

Cadent Therapeutics, Inc. develops novel small molecule therapeutics to treat schizophrenia and other cognitive disorders. It focuses on modulating synaptic plasticity, the mechanism through which the brain builds and evolves the synaptic networks that carry out cognitive functions such as learning and memory. The company was founded by Kollol Pal, Frank S. Menniti, and Bertrand Leo Chenard in 2010 and is headquartered in Cambridge, MA.

Silver Creek Pharmaceuticals, Inc. develops novel regenerative medicines. The firm focuses on treating cardiovascular disease. Its molecules are designed to promote resilience and regeneration of damaged tissues after acute or chronic injury. The company was founded in 2010 and is headquartered in San Francisco, CA.

Blackthorn Therapeutics, Inc. manufactures and markets medicines for neuro developmental disorders. The company is headquartered in San Francisco, CA.

Pamlico BioPharma, Inc. provides antibody therapeutics services. It develops fully-human monoclonal antibody (hmAb) therapeutics for the rapid diagnosis and treatment of infectious diseases and cancer. The firms lead program is focused on severe pneumonia caused by streptococcus pneumoniae (SPN), and is in preclinical IND-directed activities for a mAb cocktail and a companion point-of-care (POC) diagnostic against three serotypes that account for over 40% of SPN infections. The company was founded on 18 December, 2014 and is headquartered in Oklahoma, OK.

SSI Strategy owns and operates boutique management consulting firm. Its services include global medical affairs transformation, competency model development, post-merger integration, launch preparation, emerging markets medical affairs: organizational transformation, pharmacovigilance system enhancement and medical planning and tactic prioritization. The company was founded by Gregory Fiore in 2010 and is headquartered in Parsippany, NJ.

Novellus LLC operates as a pharmaceutical company. The company is headquartered in Cambridge, MA.

Tremeau Pharmaceuticals, Inc. engages in the developing and delivering of non-opioid pain therapies. The firm product includes TRM-201 (rofecoxib). The company was founded by Bradford C. Sippy and Mark H. N. Corrigan in 2016 and is headquartered in Concord, MA.

Sollis Therapeutics, Inc. is a clinical-stage specialty pharmaceutical company developing novel non-steroid and non-opioid analgesics. The company was founded by Gregory Fiore and Bryan Jones and is headquartered in Columbus, OH.

China Immunotech (Beijing) Biotechnology Co., Ltd. is a biotechnology company based in Beijing, China. The company's description is written in a mix of Chinese and English, making it difficult to understand. The company was founded in 2018 by Xue Qiang Zhao, Hong Li Zheng, Wei Rui, and Wei Rui has been the CEO since 2018.

Sudo Biosciences, Inc. is a biopharmaceutical company that focuses on designing and developing innovative medicines to improve the lives of patients. Sudo Biosciences is based in Menlo Park, CA, and has operations in other locations. The company's primary focus is on developing treatments that target the tyrosine kinase 2 (TYK2) pseudokinase domain, which is a crucial mediator in cytokine signaling pathways that have been associated with various immune-mediated inflammatory conditions. The CEO of the company is Scott A. Byrd.

Part of SSI Strategy LLC, Fiore Healthcare Advisors, Inc. provides pharmacovigilance and clinical research consulting services. The private company is based in Boston, MA. The company was founded by Gregory Fiore. Fiore Healthcare Advisors was acquired by SSI Strategy LLC on June 29, 2021.

Part of Inotiv, Inc., Protypia, Inc. provides targeted tissue-based protein and peptide mass spectrometry solutions. The private company is based in Nashville, TN. The company was founded in 2017 by Daniel C. Liebler. Daniel C. Liebler has been the CEO since 2017. Protypia was acquired by Inotiv, Inc. on July 07, 2022 for $11 million.